Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

118.19 +0.43 (+0.37%)
Streaming Delayed Price Updated: 1:09 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Abbott Laboratories reported Q2 sales of $10.38 billion, driven by 10.2% growth in Medical Devices, beating EPS estimates with $1.14 per share. Key highlights include FDA approval for two glucose... 
Via Benzinga
Exposures Product Safety
Why This Leading Health Stock is a Buy No Matter the Market Move
Abbott's reliable dividend is more reliable than ever and is expected to continue growing at a high-single to low-double-digit CAGR. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories Earnings Top Views, Full-Year Guidance Raised
The drugmaker slightly topped profit and sales forecasts. 
Via Investor's Business Daily
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo 
Via Benzinga
Topics Economy
Exposures Interest Rates
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
7 Analysts Have This To Say About Abbott Laboratories
Via Benzinga
Market Whales and Their Recent Bets on ABT Options
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These stocks don't appeal only to dividend seekers. 
Via The Motley Fool
Nasdaq Sees Worst Session Since 2022 As Chip Stocks Tumble After Trump's Taiwan Remarks and Biden's Potential Restrictions
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the "Neutral" zone on Wednesday. 
Via Benzinga
Topics Government
Exposures Political
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Dow Closes At New High As Q2 Earnings Season Heats Up
It’s a great start to the trading week. After months of trailing its major-index brethren, the Dow Jones reaches today’s closing bell at a new record high: 40,211. Q2 earnings are coming in well so... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Abbott Laboratories's Options: A Look at What the Big Money is Thinking
Via Benzinga
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
From Financial Buzz Media
Via GlobeNewswire
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits
Abbott faces trial over claims its baby formula causes necrotizing enterocolitis in preterm infants. This is the second trial among hundreds of similar lawsuits, impacting Abbott and Reckitt... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 MedTech Stocks to Buy for Healthy Gains
With innovations in healthcare moving at a rapid clip, investors should consider these enticing MedTech stocks to buy. 
Via InvestorPlace
Stocks Going Ex Dividend In July 2024
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
Top Analyst Reports For Abbott, BP & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
2 Magnificent Dividend Growth Stocks to Buy Now
These two dividend growth stocks are potent capital appreciation vehicles. 
Via The Motley Fool
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS